KalVista Pharmaceuticals, Inc. - KALV

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Jun 10, 2026 SCHEDULE 13G Glazer Capital, LLC 4.85% 2,581,700 View
Jun 10, 2026 SCHEDULE 13G Paul J. Glazer 4.85% 2,581,700 View
May 21, 2026 SCHEDULE 13D/A View
May 15, 2026 SCHEDULE 13G/A Point72 Asset Management, L.P. 4.2% 2,136,940 View
May 15, 2026 SCHEDULE 13G/A Point72 Capital Advisors, Inc. 4.2% 2,136,940 View
May 15, 2026 SCHEDULE 13G/A Steven A. Cohen 4.2% 2,136,940 View
May 13, 2026 SCHEDULE 13G SilverArc Capital Management, LLC 5.6% 2,876,407 View
May 13, 2026 SCHEDULE 13G Devesh Gandhi 5.6% 2,876,407 View
May 01, 2026 SCHEDULE 13G/A Integrated Core Strategies (US) LLC 3.0% 1,546,105 View
May 01, 2026 SCHEDULE 13G/A Millennium Management LLC 3.7% 1,912,146 View
May 01, 2026 SCHEDULE 13G/A Millennium Group Management LLC 3.7% 1,912,146 View
May 01, 2026 SCHEDULE 13G/A Israel A. Englander 3.7% 1,912,146 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.